ACAD vs. BHC, ARWR, RARE, MRTX, IONS, CTLT, ELAN, INSM, ROIV, and ASND
Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation.
ACADIA Pharmaceuticals has a net margin of -0.21% compared to Bausch Health Companies' net margin of -5.07%. ACADIA Pharmaceuticals' return on equity of -0.41% beat Bausch Health Companies' return on equity.
ACADIA Pharmaceuticals presently has a consensus price target of $28.94, suggesting a potential upside of 91.64%. Bausch Health Companies has a consensus price target of $11.33, suggesting a potential upside of 72.76%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Bausch Health Companies.
ACADIA Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals received 526 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 72.96% of users gave ACADIA Pharmaceuticals an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
ACADIA Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 8 articles in the media. ACADIA Pharmaceuticals' average media sentiment score of 0.21 beat Bausch Health Companies' score of -0.04 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.
Summary
ACADIA Pharmaceuticals beats Bausch Health Companies on 13 of the 17 factors compared between the two stocks.
Get ACADIA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACADIA Pharmaceuticals Competitors List
Related Companies and Tools
